At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 52 target
Drug / intervention
BL-B01D1 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Clinical Study to Evaluate the Efficacy and Safety of SI-B003 Monotherapy and BL-B01D1+SI-B003 Combination Therapy (BL-B01D1+SI-B003) in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors
In Brief
A Phase 2 clinical trial evaluating BL-B01D1 and SI-B003 for Urothelial Carcinoma and Solid Tumor. Currently recruiting, targeting 52 participants across 1 site.
Detailed Summary
This phase II study is designed to explore the efficacy and safety of SI-B003 monotherapy and BL-B01D1+SI-B003 combination therapy in patients with locally advanced or metastatic urothelial carcinoma and other solid tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUrothelial Carcinoma, Solid Tumor
CountriesChina
Collaborators--
Timeline
Phase 2Recruiting
20242025202620272028
First PostedJul 2023
Enrollment StartDec 2023
TodayJul 2026
Primary CompletionDec 2026
Study CompletionDec 2027
First PostedJul 28, 2023
Enrollment StartDec 11, 2023
Primary CompletionDec 1, 2026
Study CompletionDec 1, 2027
TodayJul 1, 2026
Enrollment to primary: 3.0 yearsPosted 2.9 years agoPrimary completion in 5 months
Interventions
BL-B01D1drug
Administration by intravenous infusion
SI-B003drug
Administration by intravenous infusion